PHIND Seminar Series:Serum Modulation of Mitochondrial Function as a Scalable Sensor of Insulin Resistance
11:00 AM – 12:00 PM: Seminar & Discussion
RSVP: https://stanford.zoom.us/webinar/register/2616009863180/WN_dbeuo7csS8q_AhR88XET0g
Presenter:
Andrew Lipchik, PhD
Postdoctoral Fellow – Michael Snyder Lab
Stanford University
Location
Webinar URL: https://stanford.zoom.us/s/96358568342
Dial: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 963 5856 8342
Password: 767148
ABSTRACT
The global epidemic of obesity is associated with the dramatic increase in the prevalence of type 2 diabetes mellitus (T2D) with an estimated 400 million people worldwide will have T2D by 2030. T2D is proceeded by insulin resistance (IR) for up to decades prior to onset of T2D. Current estimates suggest approximately one in three individuals are sufficiently insulin resistant to be at risk for IR complications including T2D, coronary heart disease and nonalcoholic fatty liver disease. IR often goes undiagnosed due to the complex, invasive and laborious nature of clamp assays preventing their universal application in the clinic. Surrogate measurements using fasting plasma glucose and insulin levels can estimate IR but are imprecise. There is a need for the identification of new biomarkers and assays for the detection and monitoring of IR. Here, we demonstrate the utility of cellular mitochondrial respiration in response to individuals’ serum as a sensor for personalized monitoring of insulin sensitivity. The modulation of insulin-dependent mitochondrial function by patient serum was highly correlated with insulin sensitivity as determined by the gold-standard modified insulin suppression test (IST). We further applied this methodology to monitor insulin sensitivity over time in response to illness as well as treatment with the insulin sensitizing medication, pioglitazone. Our results demonstrate the development and application of a novel surrogate measurement for the determination and monitoring of insulin sensitivity. This assay offers the advantages of minimal invasiveness and complexity compared to IST as well as superior correlation with IST compared to existing surrogate measurements.
ABOUT ANDREW LIPCHIK
Andrew Lipchik majored in Chemistry at Xavier University where he preformed research on the development of oxygen activation Ni(II) complexes with Dr. Craig Davis and Dr. Michael Baldwin at the University of Cincinnati. He went on to obtain his PhD from Purdue University under mentorship of Dr. Laurie Parker. His thesis work focused on identifying determinants of kinase substrate specificity. This understanding was applied to the development of novel kinase-specific peptide biosensors to monitor intracellular kinase activity. Following his graduate work, he joined the laboratory of Michael Snyder at Stanford University where he has focused on understanding the impact of the immune system on insulin resistance and glucose metabolism.
Hosted by: Garry Gold, MD
Sponsored by: PHIND Center and Department of Radiology